- Supported exchanges /
- LSE /
- 0H7R.LSE
Abeona Therapeutics Inc. (0H7R LSE) stock market data APIs
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Abeona Therapeutics Inc. Financial Data Overview
| 5.5994 | |
| 5.64 | |
| - | |
| 5.64 | |
| 5.5994 | |
| 3.12-8.8 | |
| 15 533 M | |
| 47 945 K | |
| 0 | |
| -0.2625 | |
| 1.509 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Abeona Therapeutics Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -54 747 000
- Earnings Per Share -0.808
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Abeona Therapeutics Inc. Earnings via APIs
- Latest Release 2024-08-12
- EPS/Forecast NaN
Get Abeona Therapeutics Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
